Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/3644
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJANSSENS, Jaak-
dc.contributor.authorCHIN, Y-
dc.contributor.authorDELEU, M-
dc.contributor.authorBONTE, J-
dc.contributor.authorSTAELENS, Y-
dc.date.accessioned2007-11-29T09:57:33Z-
dc.date.available2007-11-29T09:57:33Z-
dc.date.issued1993-
dc.identifier.citationANTICANCER RESEARCH, 13(6B). p. 2477-2483-
dc.identifier.issn0250-7005-
dc.identifier.urihttp://hdl.handle.net/1942/3644-
dc.description.abstractThe choice of chemotherapy for advanced breast cancer patients is based on both response rates and anticipated side effects. Two polychemotherapy regimens, ACV and NCV, were compared in an open study with 90 patients of whom 69 were evaluable both for efficacy and toxicity. Both ACV and NCV are active in metastatic breast cancer. ACV lends to more remissions in a relatively short time. NCV treatment results in a larger proportion of stable diseases. ACV causes more important alopecia, nausea and vomiting. NCV gives more anemia. The characteristics of both treatment results give the oncologist the opportunity to choose in particular clinical situations.-
dc.language.isoen-
dc.publisherINT INST ANTICANCER RESEARCH-
dc.subject.otherADVANCED BREAST CANCER; ADRIAMYCIN; MITOXANTRONE; COMBINATION CHEMOTHERAPY-
dc.titleAdriamycin, cyclophosphamide and vindesine (ACV) versus mitoxantrone, cyclophosphamide and vindesine (NCV) in advanced breast-cancer-
dc.typeJournal Contribution-
dc.identifier.epage2483-
dc.identifier.issue6B-
dc.identifier.spage2477-
dc.identifier.volume13-
local.format.pages7-
dc.description.notesLIMBURGS ONCOL CTR,HASSELT GENK,BELGIUM. CATHOLIC UNIV LEUVEN,DEPT GYNECOL ONCOL,B-3000 LOUVAIN,BELGIUM. DIENST ONCOL H HARTZIEKENHUIS,TIENEN,BELGIUM.JANSSENS, JP, LIMBURGS UNIV CENTRUM,DR L WILLEMS INST,UNIV CAMPUS GEBOUW C,B-3590 DIEPENBEEK,BELGIUM.-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.bibliographicCitation.oldjcatA1-
dc.identifier.isiA1993NE37200023-
item.contributorJANSSENS, Jaak-
item.contributorCHIN, Y-
item.contributorDELEU, M-
item.contributorBONTE, J-
item.contributorSTAELENS, Y-
item.accessRightsClosed Access-
item.fulltextNo Fulltext-
item.fullcitationJANSSENS, Jaak; CHIN, Y; DELEU, M; BONTE, J & STAELENS, Y (1993) Adriamycin, cyclophosphamide and vindesine (ACV) versus mitoxantrone, cyclophosphamide and vindesine (NCV) in advanced breast-cancer. In: ANTICANCER RESEARCH, 13(6B). p. 2477-2483.-
Appears in Collections:Research publications
Show simple item record

WEB OF SCIENCETM
Citations

3
checked on Jul 21, 2024

Page view(s)

28
checked on Oct 29, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.